Regeneron (REGN) Q2 2026: Sanofi Profit Share +59% as EYLEA HD Overtakes Legacy EYLEA
Regeneron's GAAP earnings per share fell again in the second quarter, yet the operating business grew at its fastest pace in years. Revenue rose 16.7% to $4.29 billion and operating income rose 19.8% to $1.29 billion — but net income fell 6.8% and diluted EPS slipped to $12.23 from $12.81. (On the company's adjusted basis, which excludes stock compensation, acquired IPR&D and investment marks, EPS rose about 11% to $14.29 — the gap between the two measures is itself the story of the quarter.) The entire GAAP gap sits below the operating line: smaller investment gains and a tax rate that returned to normal. Strip that away and the quarter tells a different story — a double handover, in which the Sanofi profit share has replaced legacy EYLEA as the company's growth engine, while inside the eye franchise EYLEA HD has overtaken the older drug it was built to replace.
1. Balance Sheet
1-1. Major asset items
| Item | Dec 31, 2025 ($M) | Jun 30, 2026 ($M) | Change % |
|---|---|---|---|
| Cash and cash equivalents | 3,118.1 | 2,455.8 | -21.2% |
| Marketable securities (current) | 5,487.1 | 5,538.8 | +0.9% |
| Marketable securities (noncurrent) | 10,260.6 | 9,828.3 | -4.2% |
| Accounts receivable, net | 5,741.1 | 6,565.4 | +14.4% |
| Inventories | 3,200.8 | 3,084.3 | -3.6% |
| Property, plant, and equipment, net | 5,120.4 | 5,458.9 | +6.6% |
| Intangible assets, net | 1,257.4 | 1,309.8 | +4.2% |
| Deferred tax assets | 4,077.2 | 4,381.4 | +7.5% |
| Total assets | 40,558.7 | 41,730.6 | +2.9% |
Source: Regeneron Q2 2026 Form 10-Q, condensed consolidated balance sheets.
Cash plus all marketable securities totals $17.82 billion, down 5.5% from $18.87 billion at year-end. That decline is a choice, not a squeeze — the company spent $1.96 billion on buybacks and $195 million on dividends in six months, more than the cash the business generated.
